{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:56:05Z","timestamp":1777892165978,"version":"3.51.4"},"reference-count":9,"publisher":"CSIRO Publishing","issue":"4","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":2717,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12,20]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION<\/jats:title>\n                    <jats:p>The risk of rhabdomyolysis in the general population is elevated by the increased prevalence of statin use. As the presentation of rhabdomyolysis is varied, there is a risk of delayed diagnosis leading to patient complications and increased healthcare costs. Creatine kinase (CK) alone is not sufficiently predictive for risk stratification. Beyond serum CK, other biomarkers such as transaminases may be used as surrogates to evaluate rhabdomyolysis severity and predict complication risks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>AIM<\/jats:title>\n                    <jats:p>To assess if other biomarkers are associated with peak CK and severity of rhabdomyolysis to aid in clinical diagnosis of rhabdomyolysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>A retrospective study was conducted at an acute care hospital from 2008 to 2011. Inclusion criteria were: (1) patients diagnosed with statin-induced rhabdomyolysis; and (2) peak CK levels of \u22651000 IU\/L. Patients with post-operational rhabdomyolysis, acute myocardial infarction and who had suffered from road traffic accidents were excluded. A total of 24,332 patients were screened, and 78 patients fulfilled our inclusion criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Aspartate aminotransferase (AST) was found to be positively associated with peak CK levels in the multivariable linear regression model after adjusting for alanine aminotransferase (ALT) levels (P = 0.002; \u03b2 = 83.18). Aspartate aminotransferase was found to be associated with severity of rhabdomyolysis in the multivariable logistics regression model after adjusting for ALT levels (P = 0.015; OR = 1.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION<\/jats:title>\n                    <jats:p>Aspartate transferase is associated with raised peak CK levels and severity of rhabdomyolysis. Clinicians may consider ordering AST to aid in the clinical diagnosis of rhabdomyolysis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1071\/hc17051","type":"journal-article","created":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T02:48:22Z","timestamp":1529549302000},"page":"316-320","source":"Crossref","is-referenced-by-count":7,"title":["Association of aspartate aminotransferase in statin-induced rhabdomyolysis"],"prefix":"10.1071","volume":"9","author":[{"given":"Xu Cong","family":"Ruan","sequence":"first","affiliation":[{"name":"AMD Candidate; Duke-NUS Medical School, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lian Leng","family":"Low","sequence":"additional","affiliation":[{"name":"BAssociate Consultant, Department of Family Medicine and Continuing Care, Singapore General Hospital, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu Heng","family":"Kwan","sequence":"additional","affiliation":[{"name":"CMD-PhD Candidate, Program in Health Services and Systems Research, Duke-NUS Medical School, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"67","published-online":{"date-parts":[[2017,12,12]]},"reference":[{"issue":"1","key":"2025111814120438100_R1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/01.JAA.0000510986.14286.fd","article-title":"Assessing acquired rhabdomyolysis in adults.","volume":"30","author":"Kruger","year":"2017","journal-title":"JAAPA"},{"issue":"12","key":"2025111814120438100_R2","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.clinbiochem.2017.02.016","article-title":"Non-traumatic rhabdomyolysis: background, laboratory features, and acute clinical management.","volume":"50","author":"Cervellin","year":"2017","journal-title":"Clin Biochem"},{"issue":"3","key":"2025111814120438100_R3","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/bcp.12360","article-title":"Mechanisms and assessment of statin-related muscular adverse effects.","volume":"78","author":"Mosshammer","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"2025111814120438100_R4","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1345\/aph.1Q110","article-title":"Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population.","volume":"45","author":"Amend","year":"2011","journal-title":"Ann Pharmacother"},{"issue":"19","key":"2025111814120438100_R5","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jamainternmed.2013.9774","article-title":"A risk prediction score for kidney failure or mortality in rhabdomyolysis.","volume":"173","author":"McMahon","year":"2013","journal-title":"JAMA Intern Med"},{"key":"2025111814120438100_R6","doi-asserted-by":"crossref","first-page":"h5527","DOI":"10.1136\/bmj.h5527","article-title":"STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies.","volume":"351","author":"Bossuyt","year":"2015","journal-title":"BMJ"},{"issue":"1","key":"2025111814120438100_R7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13054-016-1314-5","article-title":"Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice.","volume":"20","author":"Chavez","year":"2016","journal-title":"Crit Care"},{"key":"2025111814120438100_R8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/B978-0-12-394317-0.00015-7","article-title":"Metabolic markers in sports medicine.","volume":"56","author":"Banfi","year":"2012","journal-title":"Adv Clin Chem"},{"issue":"12","key":"2025111814120438100_R9","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1177\/000313481508101219","article-title":"Role of elevated aminotransferases in ICU patients with rhabdomyolysis.","volume":"81","author":"Raurich","year":"2015","journal-title":"Am Surg"}],"container-title":["The Journal of Primary Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/connectsci.au\/hc\/article-pdf\/9\/4\/316\/222427\/hc17051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/connectsci.au\/hc\/article-pdf\/9\/4\/316\/222427\/hc17051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T19:12:10Z","timestamp":1763493130000},"score":1,"resource":{"primary":{"URL":"https:\/\/connectsci.au\/hc\/article\/9\/4\/316\/34873\/Association-of-aspartate-aminotransferase-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,12]]},"references-count":9,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,12,12]]},"published-print":{"date-parts":[[2017,12,20]]}},"URL":"https:\/\/doi.org\/10.1071\/hc17051","relation":{},"ISSN":["1172-6156"],"issn-type":[{"value":"1172-6156","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,12]]}}}